Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Hi Kern,
Can’t help watching this even though I’m out. Still no news on the Astra vaccine contract so I presume it is dead in the water. The lack of any new contracts can’t be helping either. As for Aviva it is my largest holding by far now so hoping for a decent return.
What has caused this latest fall? I cannot find any new information and now we are solidly below £5.
Shatter; I see you are in AV as well. At least that is doing ok.
I would not expect too much from an CEO who said recently(April 2022)
"I am delighted with our performance in 2021 which was a true testament to the hard work of all our employees," said chair and interim chief executive officer Dr Roch Doliveux.
He must be blind not to see the share price which is indicative of the company's performance.
Assume their is no imminent news otherwise directors would not have been able to buy. However they may know of things in the pipeline that will come to fruition in due course.
Director buys should perhaps have been renamed desperation buys - the feeling that you have when you are in such a bad situation that you are willing to take risks in order to change it:
Well… the director buys have really worked ! As for directors selling major holdings that would be the kiss of death so they are hurting like everyone else. Other posters are hoping , if not praying, for a buyout at this lowly price. Need a contract or two to stop the rot.
I hope so. In answer to P no I am not paid to make things up. I first invested in OXB in July 2004 and have been a shareholder ever since adding here and there; sometimes at the wrong time so I now have an average of £7.24 which I hope helps explain my concern about this precipitous fall and the lack of communication from the company and my search for possible explanations.
GLALTH
Yes but there have been other director purchases recently at market prices and also Slingsby continues to hold a significant number of shares. He's not compelled to keep all the free shares he gets. Hardly rats leaving a sinking ship. Maybe they know something we don't.
I do read things and it is hard to see how this is a buy
Oxford, UK - 03 May 2022: Oxford Biomedica plc ("Oxford Biomedica" or "the Company") (LSE: OXB), was informed on 03 May 2022, that Dr. Jason Slingsby, Chief Business & Corporate Development Officer of the Group, exercised 8,712 LTIP (2018) options at nil cost on 27 April 2022, and sold all the resulting ordinary shares at 539.0p per share. Following this transaction Dr. Jason Slingsby continues to hold 120,476 options over ordinary shares.
@kernowlad Do you actually read anything before you post or you are paid to make things up, the management bought shares not dumped them and some institutions increased their positions
I am always amazed how some posters mislead the boards
Hi Kern,
Yeah, it doesn’t look very temporary, unfortunately.
Doesn't look temporary. Hard to see what will reverse this decline. Market has lost faith/patience with OXB according to the sp. The heady £15 days may be over for good so its about minimising losses now - after 20 years!
Let’s hope it’s only temporary. Oxb are going to need a miracle to stop this decline ! The vaccine contract has got to be finished whether Oxb want to admit it or not.
As usual Oxb is short on detail -The Company has fully drawn down the $85m Short Term Loan Facility with Oaktree which has been used to temporarily bridge fund the Acquisition and the $50m cash injection into Oxford Biomedica Solutions. Millions in interest on this very expensive loan/ debt. No mention of cash burn and how long before the coffers are empty ! Judging by the sp the market is not impressed .
Depending on the cash burn but yes atm they would appear to be ok. I misread the figures but with limited income and the US company seemingly making losses how long will the current cash last.
What debt? At 31 December OXB had £109m of cash and has since raised a further £80m. So, despite the US investment of c£134m, that would still leave OXB with c£55m of cash.
It's never a good sign when senior staff quickly want to dump stock and the sp has reacted accordingly.
I don't think I will average down as it has the feeling of throwing good money after bad.
Could OXB actually go under with its debt and losses without the vaccine?
Oxford, UK - 03 May 2022: Oxford Biomedica plc ("Oxford Biomedica" or "the Company") (LSE: OXB), was informed on 03 May 2022, that Dr. Jason Slingsby, Chief Business & Corporate Development Officer of the Group, exercised 8,712 LTIP (2018) options at nil cost on 27 April 2022, and sold all the resulting ordinary shares at 539.0p per share.
Morning Kern,
Don’t know about sound judgement ! It’s difficult to know what to do at the moment. As we know from experience this can be very volatile, a slow burner and took what seemed like a lifetime to reach its previous highs. The Astra contract must be mostly priced in so it’s a case of can they continue to pay their bills and can they turn Homology to profit ?
I am not so sure that we won’t see another fund raising in the coming months if they don’t secure some decent contracts but who knows what is in the pipeline? Oxb certainly won’t give us any hints.. sorry can’t be any help..
Hi Shatter
We always knew communications were not the best (understatement) and cash burn an issue but I never thought we would see those days back. Agree with your diagnosis and am wondering whether i should lower my average or whether that is just pouring good money. If you buy back in let me know as your judgement seems sounder than mine!
Cheers
K
Hi Kern
It does look like we have been kept in the dark concerning the Astra contract. No mention of when they stopped manufacture of the vaccine ? Why they went ahead with the Homology purchase is beyond me and seemingly the CEO and Diggle amongst others.
I would have considered buying back in at some point if the conditions were right but I don’t trust the directors. There appears to be a worldwide over supply of vaccines ( which is great) but not good news for Oxb and another contract. It’s supply and demand and there doesn’t appear to be a demand at the moment.
I hope they can pull a rabbit out of the hat and turn Homology around as cash burn is a real issue ‘again’. Just like the good old days..
I have been incommunicado for a while so this is a bit of a shock. If I can get back to even I am out which after all these years is very sad but I now have little faith in their ability to turn this around especially as they keep shareholders in the dark as much as they can legally get away with.
I emailed them about the AZ contract and didn't get an answer which is unforgivable really. Desperately disappointing.
From Investors Chronicle…
Covid-19 proved to be a boon for certain companies, but pandemic-linked benefits are beginning to dissipate. Oxford BioMedica’s (OXB) share price has been in retreat since the beginning of November. That trend was maintained on results day as the vaccine manufacturer guided for reduced revenue in 2022 due to a pause in vaccine manufacturing activity. Much depends on the outcome of negotiations with AstraZeneca (AZN) over a possible extension to a supply agreement in relation to its Covid-19 vaccine.
Put simply, the trajectory of the share price remains intertwined with the clinical relationship with AstraZeneca. It’s no surprise, therefore, that short positions on the stock increased throughout March.
Is the sp sitting in limbo waiting for news from Astra? I have a notion that this “pause” is permanent . There must be a certain amount of this built into the sp at present but I wouldn’t rule out a further drop if Oxb ever get round to telling its shareholders that talks with Astra have come to nowt if that is the case. It unfortunately took Oxb months to tell us about the “pause”.
Hi
Do you really think there’s any mileage in this atall?
Washed my face here many months ago. Interesting you still interested in this?
Starting to reek of desperation…
I'm a pre-Covid investor so never considered mass vaccine production as anything other than temporary (just icing on the cake). Obviously there were some (many) investors only along for the vaccine ride and I imagine yesterday's price fall has shaken a lot of them loose. Get used to the post Covid reality; the potential value in OXB is not, and never was, in whether it was manufacturing AZ's Covid vaccine. The income has been welcome but OXB has never planned to be a long-term vaccine manufacturer